Clinical Trial

Salivary Oxytocin as a Biomarker of Psychedelic Treatment

Study acronym: PAPOXT_MDD
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated January 16, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
Trial Details
NCT Number NCT07345858
Lead Sponsor University of Geneva, Switzerland
Conditions Major Depressive Disorder (MDD)
Enrollment 80 participants
Start Date 2026-01-05
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-16